Test Price
2,800 AED✅ Home Collection Available
CAPN3 Gene Limb‑Girdle Muscular Dystrophy Type 2A (LGMD2A) Genetic Test in UAE
Executive Summary & Core Metrics
Diagnostic accuracy of 99.9% sensitivity via ISO 9001:2015 accredited NGS processing. Includes VIP mobile phlebotomy home collection with temperature‑controlled cold‑chain logistics, and post‑test clinical genetic counseling by a DHA‑licensed consultant medical geneticist. Insurance pre‑verification is available through WhatsApp.
Test Overview & Methodology
The CAPN3 Gene Limb‑Girdle Muscular Dystrophy Type 2A (LGMD2A) Genetic Test detects pathogenic variants in the CAPN3 gene using Next‑Generation Sequencing (NGS), providing a definitive molecular diagnosis for limb‑girdle muscular dystrophy type 2A. This test is essential for confirming clinical suspicion, enabling carrier screening, and guiding family planning decisions.
| Parameter | Our Test (NGS Sequencing) | Closest Alternative (Conventional Single‑Gene Test) |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) – full gene coverage | Sanger sequencing – limited exons |
| Variant Detection Rate | >99% for pathogenic variants | ~80% (misses deep intronic variants) |
| Turnaround Time | 3 to 4 Weeks | 5 to 7 Weeks |
| Cost | 2,800 AED | Often >3,200 AED (cumulative exons) |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I understand the profound implications of genetic testing for families affected by muscular dystrophy. This test illuminates the molecular cause of LGMD2A, empowering families with reproductive options and personalised surveillance. However, every result must be correlated with clinical findings and expert genetic counselling. Never base therapeutic decisions solely on a lab report.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Medication Advisory
Do not discontinue any prescribed medication or supplement without consulting your treating physician. Genetic test results do not replace clinical management.
Safety Exclusion Criteria & Emergency Red Flags
- Recent blood transfusion (<2 weeks) may interfere with DNA quality – notify our team to reschedule collection.
- Patients on chronic anticoagulants should inform the phlebotomist for precautionary measures.
- Seek immediate emergency care if: sudden worsening of muscle weakness, difficulty breathing, chest pain, or loss of consciousness.
Patient FAQ & Clinical Guidance
1. What does the CAPN3 gene test diagnose, and who should consider it?
This test identifies pathogenic mutations in the CAPN3 gene responsible for limb‑girdle muscular dystrophy type 2A. It aids in diagnosis, carrier screening, and family planning. It is recommended for individuals with progressive proximal muscle weakness or a family history of LGMD2A.
2. How long does it take to receive results, and what do they mean clinically?
Results are delivered within 3 to 4 weeks. The comprehensive report includes variant classification (pathogenic, likely pathogenic, or variant of uncertain significance) interpreted by a clinical geneticist alongside your neurologist.
3. Is home sample collection available across all UAE emirates?
Yes, our ISO‑certified mobile phlebotomy team performs VIP home draws daily from 8 AM to 11 PM, using validated cold‑chain transport to preserve DNA integrity. Service covers Dubai, Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, Fujairah, and Umm Al Quwain.
4. Will genetic counseling be provided after the test?
Yes, every patient receives post‑test genetic counseling from the ordering clinician and a DHA‑licensed consultant medical geneticist to interpret results and discuss implications for family members.
UAE Regulatory & Data Privacy Adherence
This test is performed under DHA Facility License Number 1143 at DNA Labs UAE. All sample handling, data storage, and reporting comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | CAPN3 Gene Limb‑Girdle Muscular Dystrophy Type 2A (LGMD2A) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 weeks |
| Sample Type / Matrix | Whole Blood (EDTA) – 5 mL |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full Gene Coverage |
| ICD-10-CM Code | G71.0 |
| LOINC Code | 21636-6 |
| DHA Facility License & Address | License No.: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians